DeepMed Research

ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Ingenol Mebutate 0.015%

First Posted Date: 2013-04-19

Last Posted Date: 2013-12-31

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT01836367

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Cerebral Oxygen Monitoring During Surgery and Recovery After Surgery in Patients Having Lung Surgery

Terminated

Conditions: Cerebral Oxygen Desaturation

First Posted Date: 2013-04-18

Last Posted Date: 2017-02-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 130

Registration Number: NCT01835327

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Women's INternational Transcatheter Aortic Valve Implantation Registry

Completed

Conditions: Symptomatic Aortic Stenosis

First Posted Date: 2013-03-27

Last Posted Date: 2018-05-04

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 1019

Registration Number: NCT01819181

Locations: 🇮🇹
Instituto Clinico Humanitas, Milan, Italy
🇫🇷
Hôpital Privé Parly 2, Le Chesnay, France
🇬🇧
Imperial College, London, United Kingdom

and more 7 locations

Methodology Issues in a Tailored Light Treatment for Persons With Dementia

Not Applicable

Completed

Conditions: Depression
Sleep Disturbances

Interventions: Other: Inactive intervention
Other: Tailored Active intervention

First Posted Date: 2013-03-22

Last Posted Date: 2024-06-04

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 45

Registration Number: NCT01816152

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium

Completed

Conditions: Early Onset CAD
Fibromuscular Dysplasia

First Posted Date: 2013-03-11

Last Posted Date: 2013-11-05

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 34

Registration Number: NCT01808729

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Systane Ultra Versus Maxidex Versus Saline

Not Applicable

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Systane Ultra
Drug: Saline solution
Drug: Maxidex

First Posted Date: 2013-01-25

Last Posted Date: 2013-01-25

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 36

Registration Number: NCT01775540

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation

Phase 4

Terminated

Conditions: Nicotine Addiction

Interventions: Other: Basic Advice + Placebo Drug
Other: Scheduled Gradual Reduction + Varenicline
Other: Basic Advice + Varenicline
Other: Scheduled Gradual Reduction + Placebo Drug

First Posted Date: 2013-01-21

Last Posted Date: 2016-03-16

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 32

Registration Number: NCT01772641

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Cyclophosphamide

First Posted Date: 2012-12-04

Last Posted Date: 2017-12-06

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 10

Registration Number: NCT01740401

Locations: 🇺🇸
New York University Langone Clinical Cancer Center, New York, New York, United States

Abiraterone Acetate Trial in African American Prostate Cancer Patients

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone Acetate

First Posted Date: 2012-11-28

Last Posted Date: 2017-05-12

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 11

Registration Number: NCT01735396

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Queens Cancer Center, Queens Hospital, New York, New York, United States

Online Emotional Regulation Group Treatment

Phase 1

Completed

Conditions: Emotional Dysregulation
Executive Dysfunction
Traumatic Brain Injury

Interventions: Behavioral: Online Emotional Regulation Treatment

First Posted Date: 2012-11-21

Last Posted Date: 2015-10-02

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 147

Registration Number: NCT01730261

Locations: 🇺🇸
The Brain Injury Research Center at Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy